(Q37469438)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19414111%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

review article

1 reference

title

Clinical implications of hypoxia inducible factor in renal cell carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19414111%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19414111%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

Marc C Smaldone

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19414111%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

publication date

1 May 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19414111%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19414111%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19414111%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

238-245

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19414111%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19414111%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

cites work

Cancer statistics, 2006

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

The changing natural history of renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Expression of ARNT, ARNT2, HIF1 alpha, HIF2 alpha and Ah receptor mRNAs in the developing mouse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Characterization of an oxygen/redox-dependent degradation domain of hypoxia-inducible factor alpha (HIF-alpha) proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Hypoxia-inducible factor asparaginyl hydroxylase (FIH-1) catalyses hydroxylation at the beta-carbon of asparagine-803

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Mutations of the VHL tumour suppressor gene in renal carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Regulation of HIF prolyl hydroxylases by hypoxia-inducible factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

HIF-1 alpha is required for solid tumor formation and embryonic vascularization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

The hypoxia-responsive transcription factor EPAS1 is essential for catecholamine homeostasis and protection against heart failure during embryonic development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Phenotypic persistence after reoxygenation of hypoxic neuroblastoma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

HIF activation identifies early lesions in VHL kidneys: evidence for site-specific tumor suppressor function in the nephron

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Human HIF-3alpha4 is a dominant-negative regulator of HIF-1 and is down-regulated in renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Molecular pathways in renal cell carcinoma--rationale for targeted treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

The contribution of VHL substrate binding and HIF1-alpha to the phenotype of VHL loss in renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Inhibition of HIF2alpha is sufficient to suppress pVHL-defective tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von Hippel-Lindau disease-associated vascular tumors in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Redox regulation of the hypoxia-inducible factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Antioxidant/pro-oxidant equilibrium regulates HIF-1alpha and NF-kappa B redox sensitivity. Evidence for inhibition by glutathione oxidation in alveolar epithelial cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

A non-hypoxic, ROS-sensitive pathway mediates TNF-alpha-dependent regulation of HIF-1alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

IL-1beta-mediated up-regulation of HIF-1alpha via an NFkappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Redox-sensitive regulation of the HIF pathway under non-hypoxic conditions in pulmonary artery smooth muscle cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

A novel superoxide-producing NAD(P)H oxidase in kidney

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Nox4 is critical for hypoxia-inducible factor 2-alpha transcriptional activity in von Hippel-Lindau-deficient renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

NAD(P)H oxidases regulate HIF-2alpha protein expression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Aryl hydrocarbon nuclear translocator (ARNT) promotes oxygen-independent stabilization of hypoxia-inducible factor-1alpha by modulating an Hsp90-dependent regulatory pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Development of novel therapeutic strategies that target HIF-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

The Akt-mTOR tango and its relevance to cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Targeting HIF-1 for cancer therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Phosphorylated KDR is expressed in the neoplastic and stromal elements of human renal tumours and shuttles from cell membrane to nucleus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Sunitinib in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Tumorigenesis and the angiogenic switch

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

A phase II study of flavopiridol in patients with advanced renal cell carcinoma: results of Southwest Oncology Group Trial 0109.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

A clinical trial with chimeric monoclonal antibody WX-G250 and low dose interleukin-2 pulsing scheme for advanced renal cell carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Up-regulation of c-met protooncogene product expression through hypoxia-inducible factor-1alpha is involved in trophoblast invasion under low-oxygen tension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Overexpression of the met/HGF receptor in renal cell carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Suppression of tumor growth through disruption of hypoxia-inducible transcription

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1alpha

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2007.12.001

10.1016/J.UROLONC.2007.12.001

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19414111%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference